News center | Australia

Philips Launches DreamMapper in the UK, Completing the Dream Family Suite to Support Improved Therapy Adherence for People Living with Sleep Apnoea

June 29, 2016

Guildford, UKRoyal Philips (NYSE: PHG; AEX: PHIA) has today announced the UK launch of the DreamMapper app and website, designed to assist people living with sleep apnoea to improve treatment adherence by providing tools and real time tracking and analysis of their positive airway pressure (PAP) therapy. DreamMapper works as part of the Philips Dream Family portfolio which includes DreamStation, a sleep therapy system, and DreamWear, a minimal contact nasal mask. This system uses patient-designed therapy devices and the latest in data mobilisation technology to help people best manage their sleep apnoea.

DreamMapper is now available in the UK for Android and Apple smartphones, tablets and desktop systems and quickly correlates and analyses data on therapy usage, mask fit and apnoea hypopnea index (AHI) readings to help improve treatment success as well as helping users set and achieve personal therapy goals. In addition to providing continuous therapy analysis, the platform also provides troubleshooting support, conveniently supplying users with instructional videos that address a variety of potential therapy challenges. In turn this has the potential to reduce NHS clinician contact time, freeing up hours away from more administrative therapy enquiries.

Karen Danville from Hull was one of the first people to benefit from DreamMapper in the UK, stating; “I check DreamMapper every morning as I wake up to see how much therapy time I have had and how good my mask fit was. It also has some helpful information about sleep apnoea. I would highly recommend this app to all my fellow sleep apnoea sufferers. I love it.”

 

Working as part of the Dream Family suite, clinicians also see the benefits as DreamMapper connects and monitors the patient’s use of DreamStation, an important part of PAP delivery and adherence, as Hannah Hunt, respiratory physiologist at Llandough Hospital in Wales explains: “Patients like that it (DreamStation) isn’t an obvious medical device at first glance, while it’s one of the simplest devices we have come across for both patients and us. Accessing the clinical menu is simple, and patients are able to look at as much or as little data as they require. The Three Night Summary that pops up in the morning is a great feature as it gives them a quick guide to how they are complying with treatment. We look forward to being able to enhance our patients’ experience further with DreamMapper.”


To help enhance the patient experience, DreamMapper also provides motivation enhancement therapy coaching tools to inspire users and encourage adherence. Bernadette Coleman from Philips remarks, “We’re very excited about the potential of DreamMapper to enable people living with sleep apnoea to take control of their own care by supporting them with technology that’s integrated into their therapy. Global statistics have shown that DreamMapper can improve sleep therapy adherence by 22%[1] and we look forward to seeing similar benefits in the UK.”

 

For more information on DreamMapper or any of the Dream Family range, please visit: https://www.philips.co.uk/healthcare/consumer/sleep-apnea/living-with-sleep-apnoea/dream-family

 

Twitter: @PhilipsUK – #DreamMapper

Facebook: PhilipsRespironicsUK


[1] ‘SystemOne retrospective study’, Philips Respironics, 2015

For further information, please contact:

Jonathan Falcone

Philips Media Relations

Tel: +44 (0)7711 462 856

E-mail: jonathan.falcone@philips.com

About Sleep Apnoea

Obstructive Sleep Apnoea (OSA) is a serious condition where the muscles in the throat relax during sleep causing the sufferer to temporarily stop breathing. If untreated it can occur hundreds of times in a night leading to daytime fatigue and other serious health problems. Once diagnosed it can be easily treated through lifestyle changes, using a continuous positive airway pressure (CPAP) device or wearing a mandibular advancement device (MAD).

About DreamMapper

DreamMapper is a mobile app that allows you to track your therapy progress so you can take an active role in your sleep apnoea therapy. You can also access DreamMapper through any browser. DreamMapper provides feedback on your therapy usage, mask fit and apnoea hypopnea index (AHI). You can also access videos and guides to learn more about obstructive sleep apnoea and your Philips Respironics DreamStation or System One sleep therapy equipment. You can also set custom goals and unlock achievements to stay motivated, and set reminders for when it’s time to clean or replace equipment.

About Dream Station

DreamStation positive airway pressure (PAP) sleep therapy devices are designed to be as comfortable and easy to experience as sleep is intended to be. Connecting patients and care teams, DreamStation devices empower users with sleep apnoea to embrace their care with confidence, and enable care teams to practice efficient and effective patient management.

About Royal Philips

Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people’s health and enabling better outcomes across the health continuum from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. The company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Philips’ wholly owned subsidiary Philips Lighting is the global leader in lighting products, systems and services. Headquartered in the Netherlands, Philips posted 2015 sales of EUR 24.2 billion and employs approximately 104,000 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.

You are about to visit a Philips global content page

Continue

Our site can best be viewed with the latest version of Microsoft Edge, Google Chrome or Firefox.